Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: Ravulizumab to Prevent AKI in CKD Patients Undergoing Cardiac Surgery
NCT05746559Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of ravulizumab in acute kidney injury (AKI), sponsored by Alexion Pharmaceuticals. Started Apr 2023; status: terminated.
02
Drugs
ravulizumab
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05746559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746559.